{"hands_on_practices": [{"introduction": "The mechanism of action for a DPP-4 inhibitor like sitagliptin begins at the molecular level: its ability to bind to the active site of the DPP-4 enzyme. This exercise explores the fundamental principles of competitive, reversible inhibition. By deriving and applying the fractional occupancy formula, you will gain a quantitative understanding of how a drug's concentration and its binding affinity, represented by the dissociation constant $K_{i}$, determine the extent to which the target enzyme is inhibited [@problem_id:4958112].", "problem": "Dipeptidyl peptidase-4 (DPP-4) is a serine protease that cleaves incretin hormones such as glucagon-like peptide-1 (GLP-1). Small-molecule inhibitors like sitagliptin bind reversibly to the DPP-4 active site and compete with substrate for binding, which is the defining feature of competitive, reversible inhibition: the inhibitor binds to the same site as the substrate through noncovalent interactions that are at equilibrium and dissociable. In a substrate-free in vitro system at equilibrium, consider the enzyme-inhibitor binding scheme\n$$\nE + I \\rightleftharpoons EI,\n$$\nwith the equilibrium dissociation constant defined by the law of mass action as\n$$\nK_{i} \\equiv \\frac{[E][I]}{[EI]}.\n$$\nLet the total enzyme concentration be conserved as\n$$\n[E]_{\\text{tot}} = [E] + [EI].\n$$\nStarting only from these definitions, derive an expression for the fractional occupancy of DPP-4 by inhibitor,\n$$\nf \\equiv \\frac{[EI]}{[E]_{\\text{tot}}},\n$$\nin terms of $[I]$ and $K_{i}$, and then evaluate $f$ numerically for sitagliptin with $K_{i} = 18 \\ \\text{nM}$ at a free inhibitor concentration of $[I] = 72 \\ \\text{nM}$. Express the final result as a unitless decimal fraction and round your answer to $3$ significant figures.", "solution": "The problem statement is analyzed and found to be valid. It is scientifically grounded in the principles of enzyme kinetics and chemical equilibrium, is well-posed with sufficient and consistent information, and is expressed objectively. No flaws corresponding to the invalidity criteria are present.\n\nThe primary objective is to derive an expression for the fractional occupancy of the enzyme DPP-4 by an inhibitor, denoted as $f$, and then to calculate its numerical value for given concentrations.\n\nThe fractional occupancy, $f$, is defined as the ratio of the concentration of the enzyme-inhibitor complex, $[EI]$, to the total enzyme concentration, $[E]_{\\text{tot}}$:\n$$\nf \\equiv \\frac{[EI]}{[E]_{\\text{tot}}}\n$$\nThe total enzyme concentration is conserved, meaning it is the sum of the free enzyme concentration, $[E]$, and the concentration of the enzyme-inhibitor complex, $[EI]$:\n$$\n[E]_{\\text{tot}} = [E] + [EI]\n$$\nSubstituting this conservation equation into the definition of $f$ yields:\n$$\nf = \\frac{[EI]}{[E] + [EI]}\n$$\nTo express $f$ in terms of the free inhibitor concentration, $[I]$, and the equilibrium dissociation constant, $K_i$, we must eliminate $[E]$ from the equation. The equilibrium dissociation constant for the reaction $E + I \\rightleftharpoons EI$ is given by the law of mass action:\n$$\nK_{i} \\equiv \\frac{[E][I]}{[EI]}\n$$\nThis equation can be rearranged to express the free enzyme concentration, $[E]$, in terms of other species:\n$$\n[E] = K_i \\frac{[EI]}{[I]}\n$$\nNow, we substitute this expression for $[E]$ back into our equation for $f$:\n$$\nf = \\frac{[EI]}{K_i \\frac{[EI]}{[I]} + [EI]}\n$$\nThe term $[EI]$ is common to the numerator and both terms in the denominator's sum. It can be factored out from the denominator:\n$$\nf = \\frac{[EI]}{[EI] \\left( \\frac{K_i}{[I]} + 1 \\right)}\n$$\nCanceling the $[EI]$ term from the numerator and denominator gives:\n$$\nf = \\frac{1}{\\frac{K_i}{[I]} + 1}\n$$\nTo simplify this expression into a more conventional form, we can multiply the numerator and the denominator by $[I]$:\n$$\nf = \\frac{1 \\cdot [I]}{\\left( \\frac{K_i}{[I]} + 1 \\right) \\cdot [I]} = \\frac{[I]}{K_i + [I]}\n$$\nThis is the final derived expression for the fractional occupancy, $f$, in terms of $[I]$ and $K_i$.\n\nNext, we evaluate $f$ numerically using the provided values for sitagliptin: $K_i = 18 \\ \\text{nM}$ and $[I] = 72 \\ \\text{nM}$.\nSubstituting these values into the derived formula:\n$$\nf = \\frac{72 \\ \\text{nM}}{18 \\ \\text{nM} + 72 \\ \\text{nM}}\n$$\nThe concentration units (nM) in the numerator and denominator cancel, yielding a dimensionless fraction as expected.\n$$\nf = \\frac{72}{90} = \\frac{8 \\times 9}{10 \\times 9} = \\frac{8}{10} = 0.8\n$$\nThe problem requires the final result to be rounded to $3$ significant figures. Therefore, the value $0.8$ is expressed as $0.800$.", "answer": "$$\n\\boxed{0.800}\n$$", "id": "4958112"}, {"introduction": "While DPP-4 inhibitors work by preserving endogenous GLP-1, GLP-1 receptor agonists are synthetic analogs designed for greater stability and a longer duration of action. A crucial pharmacokinetic parameter defining this duration is the half-life ($t_{1/2}$). This practice challenges you to connect fundamental pharmacokinetic concepts—clearance ($CL$) and volume of distribution ($V$)—to derive the half-life and then apply this relationship to calculate the remarkably long duration of a modern agonist like semaglutide [@problem_id:4958146].", "problem": "A glucagon-like peptide-1 receptor agonist (GLP-1RA) administered systemically is modeled by a one-compartment disposition with first-order elimination. Starting from the definition of clearance and volume of distribution, derive the expression for the effective terminal half-life in terms of the volume of distribution $V$ and the clearance $CL$, under the assumption of first-order elimination. Then, using the derived expression, calculate the half-life for semaglutide given the following typical adult pharmacokinetic parameters: $V = 12.5 \\ \\text{L}$ and $CL = 0.050 \\ \\text{L/h}$. Express your final answer in hours and round to three significant figures. Also briefly justify why dipeptidyl peptidase-4 (DPP-4) inhibition changes the half-life of endogenous glucagon-like peptide-1 (GLP-1) in this framework but is not expected to change the half-life of a DPP-4–resistant GLP-1RA like semaglutide.", "solution": "The fundamental base is first-order elimination kinetics in a one-compartment model, together with core pharmacokinetic definitions. Let $C(t)$ denote the plasma concentration of the drug at time $t$. Under first-order elimination, the rate of change of concentration is proportional to the concentration:\n$$\n\\frac{dC(t)}{dt} = -k\\,C(t),\n$$\nwhere $k$ is the first-order elimination rate constant. The solution of this differential equation with initial condition $C(0)=C_{0}$ is\n$$\nC(t) = C_{0}\\,\\exp(-k\\,t).\n$$\nThe effective terminal half-life $t_{1/2}$ is defined as the time required for the concentration to decrease to one-half of its initial value:\n$$\nC(t_{1/2}) = \\frac{1}{2}C_{0}.\n$$\nSubstituting the exponential solution and solving for $t_{1/2}$,\n$$\nC_{0}\\,\\exp(-k\\,t_{1/2}) = \\frac{1}{2}C_{0}\n\\quad\\Rightarrow\\quad\n\\exp(-k\\,t_{1/2}) = \\frac{1}{2}\n\\quad\\Rightarrow\\quad\n-k\\,t_{1/2} = \\ln\\!\\left(\\frac{1}{2}\\right) = -\\ln 2\n\\quad\\Rightarrow\\quad\nt_{1/2} = \\frac{\\ln 2}{k}.\n$$\nTo connect $k$ to the core pharmacokinetic parameters, we use the definition of clearance in a one-compartment model. Clearance $CL$ is the proportionality constant that relates the rate of elimination to the concentration, and the elimination rate constant satisfies\n$$\nk = \\frac{CL}{V},\n$$\nwhere $V$ is the volume of distribution. Substituting this relation into the expression for $t_{1/2}$ gives\n$$\nt_{1/2} = \\frac{\\ln 2}{k} = \\frac{\\ln 2}{CL/V} = \\frac{\\ln 2 \\cdot V}{CL}.\n$$\nNow compute $t_{1/2}$ for semaglutide using $V = 12.5 \\ \\text{L}$ and $CL = 0.050 \\ \\text{L/h}$:\n$$\nt_{1/2} = \\frac{\\ln 2 \\cdot 12.5}{0.050}.\n$$\nUsing $\\ln 2 \\approx 0.693147\\,$,\n$$\nt_{1/2} \\approx \\frac{0.693147 \\times 12.5}{0.050} = \\frac{8.6643375}{0.050} = 173.28675\\ \\text{hours}.\n$$\nRounded to three significant figures and expressed in hours, this is $173$ hours.\n\nFinally, regarding dipeptidyl peptidase-4 (DPP-4) inhibition: DPP-4 inhibition reduces enzymatic degradation of endogenous glucagon-like peptide-1 (GLP-1), effectively decreasing the metabolic component of $CL$ for endogenous GLP-1, which increases $t_{1/2}$ via $t_{1/2} = \\frac{\\ln 2 \\cdot V}{CL}$. In contrast, semaglutide is engineered to be resistant to DPP-4 cleavage; therefore, DPP-4 inhibition does not materially reduce its $CL$, and its $t_{1/2}$ remains governed by non–DPP-4 pathways and the parameters $V$ and $CL$ shown above.", "answer": "$$\\boxed{173}$$", "id": "4958146"}, {"introduction": "The ultimate therapeutic goal of incretin-based therapies is to enhance glucose-dependent insulin secretion. This final practice bridges the gap between drug concentration and physiological effect using a classic pharmacodynamic ($E_{max}$) model. You will calculate the fold-increase in insulin secretion in response to elevated GLP-1 levels, providing a concrete example of how pharmacologists model the concentration-response relationship to predict a drug's efficacy [@problem_id:4958189].", "problem": "A patient with type 2 diabetes mellitus is treated with a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the circulating active glucagon-like peptide-1 (GLP-1). Postprandial plasma active GLP-1 concentration is measured at $C = 20 \\ \\text{pmol} \\cdot \\text{L}^{-1}$. In a validated in vitro to in vivo translational pharmacodynamic system for the GLP-1 receptor on pancreatic $\\beta$-cells, basal insulin secretion (in the absence of GLP-1 stimulation) is $E_{0} = 60 \\ \\text{pmol} \\cdot \\text{min}^{-1}$, the maximum GLP-1–mediated increase above basal is $E_{\\max} = 220 \\ \\text{pmol} \\cdot \\text{min}^{-1}$, the concentration producing half-maximal effect is $EC_{50} = 15 \\ \\text{pmol} \\cdot \\text{L}^{-1}$, and the Hill coefficient is $n = 1$.\n\nStarting from the receptor occupancy concept and the assumption that effect is proportional to occupancy in a saturable system with possible cooperativity, derive the appropriate expression linking $E$ to $C$, and then compute the fold-change in insulin secretion relative to basal, defined as $E/E_{0}$, at the measured $C$. Report your final result as a pure number (dimensionless) and round your answer to four significant figures.", "solution": "The problem requires the derivation of a pharmacodynamic model and the calculation of a specific physiological response. The validation process has confirmed the problem is scientifically sound, well-posed, and contains all necessary data.\n\nThe relationship between the drug concentration and the pharmacological effect is described by the Hill-Langmuir equation. This model is derived from the principles of receptor theory, assuming the law of mass action for the binding of a ligand (in this case, GLP-1) to its receptor.\n\nLet $C$ represent the concentration of the ligand (active GLP-1). Let $\\theta$ be the fractional receptor occupancy, defined as the fraction of total receptors that are bound by the ligand. For a system with a single binding site and no cooperativity, the fractional occupancy is related to the ligand concentration $C$ and the dissociation constant $K_d$ by the Langmuir isotherm:\n$$ \\theta = \\frac{C}{C + K_d} $$\nThe dissociation constant $K_d$ is the concentration at which half of the receptors are occupied.\n\nThe problem describes a more general case that allows for cooperativity, characterized by the Hill coefficient $n$. The generalized expression for fractional occupancy becomes:\n$$ \\theta = \\frac{C^n}{C^n + K_A^n} $$\nwhere $K_A$ is the ligand concentration that produces half-maximal occupancy. The problem provides the parameter $EC_{50}$, the concentration that produces half of the maximal effect. Assuming that fractional occupancy is directly proportional to the drug-induced effect, we can substitute $EC_{50}$ for $K_A$.\n\nThe pharmacological effect, $E$, is the sum of the basal effect, $E_0$ (the effect in the absence of the drug, $C=0$), and the effect stimulated by the drug, $E_{stim}$. The stimulated effect is assumed to be proportional to the fractional receptor occupancy, $\\theta$, and scaled by the maximum possible stimulated effect, $E_{max}$. The problem defines $E_{max}$ as the \"maximum GLP-1–mediated increase above basal\".\nTherefore, the stimulated effect is:\n$$ E_{stim} = E_{max} \\cdot \\theta = E_{max} \\frac{C^n}{C^n + EC_{50}^n} $$\n\nThe total effect, $E$, is the sum of the basal and stimulated effects:\n$$ E(C) = E_0 + E_{stim} = E_0 + E_{max} \\frac{C^n}{C^n + EC_{50}^n} $$\nThis is the derived expression linking the total insulin secretion rate $E$ to the GLP-1 concentration $C$.\n\nThe problem provides the following values:\nBasal insulin secretion, $E_0 = 60 \\ \\text{pmol} \\cdot \\text{min}^{-1}$.\nMaximum increase above basal, $E_{max} = 220 \\ \\text{pmol} \\cdot \\text{min}^{-1}$.\nHalf-maximal effective concentration, $EC_{50} = 15 \\ \\text{pmol} \\cdot \\text{L}^{-1}$.\nPostprandial GLP-1 concentration, $C = 20 \\ \\text{pmol} \\cdot \\text{L}^{-1}$.\nHill coefficient, $n = 1$.\n\nSubstituting $n=1$ into the general equation simplifies it to the Michaelis-Menten form, consistent with the simple binding model previously described:\n$$ E(C) = E_0 + E_{max} \\frac{C}{C + EC_{50}} $$\n\nWe are asked to compute the fold-change in insulin secretion relative to basal, which is the ratio $\\frac{E}{E_0}$.\n$$ \\frac{E}{E_0} = \\frac{E_0 + E_{max} \\frac{C}{C + EC_{50}}}{E_0} $$\n$$ \\frac{E}{E_0} = 1 + \\left(\\frac{E_{max}}{E_0}\\right) \\frac{C}{C + EC_{50}} $$\n\nNow, we substitute the given numerical values into this expression.\nThe ratio of maximum increase to basal effect is:\n$$ \\frac{E_{max}}{E_0} = \\frac{220 \\ \\text{pmol} \\cdot \\text{min}^{-1}}{60 \\ \\text{pmol} \\cdot \\text{min}^{-1}} = \\frac{22}{6} = \\frac{11}{3} $$\nThe fractional saturation term is:\n$$ \\frac{C}{C + EC_{50}} = \\frac{20 \\ \\text{pmol} \\cdot \\text{L}^{-1}}{20 \\ \\text{pmol} \\cdot \\text{L}^{-1} + 15 \\ \\text{pmol} \\cdot \\text{L}^{-1}} = \\frac{20}{35} = \\frac{4}{7} $$\n\nSubstituting these results back into the equation for the fold-change:\n$$ \\frac{E}{E_0} = 1 + \\left(\\frac{11}{3}\\right) \\left(\\frac{4}{7}\\right) = 1 + \\frac{44}{21} $$\nTo perform the addition, we use a common denominator:\n$$ \\frac{E}{E_0} = \\frac{21}{21} + \\frac{44}{21} = \\frac{65}{21} $$\n\nThe problem requires the final answer as a pure number rounded to four significant figures.\n$$ \\frac{65}{21} \\approx 3.095238095... $$\nRounding this value to four significant figures gives $3.095$.", "answer": "$$\\boxed{3.095}$$", "id": "4958189"}]}